Answer & Explanation

Efficacy of Pfizer-BioNTech COVID-19 vaccine on adolescents Description: You have the data set from Pfizer-BioNtech’s Phase 3 trial of their COVID-19 vaccine in adolescents 12 to 15 years old. This was an experiment with controls. Efficacy of Pfizer-BioNTech COVID-19 vaccine on adolescents Description On March 31, 2021, Pfizer and BioNTech announced that “in a Phase 3 trial in adolescents 12 to 15 years of age with or without prior evidence of SARS-CoV-2 infection, the Pfizer-BioNTech COVID-19 vaccine BNT162b2 demonstrated 100% efficacy and robust antibody responses, exceeding those recorded earlier in vaccinated participants aged 16 to 25 years old, and was well tolerated.” These results are from a Phase 3 trial in 2,260 adolescents 12 to 15 years of age in the United States. In the trial, 18 cases of COVID-19 were observed in the placebo group (n = 1,129) versus none in the vaccinated group (n = 1,131). Data Format (data file Download data file): A data frame with 2260 observations on the following 2 variables group- Study group: vaccine or placebo outcome- Study outcome: COVID-19 infection or no COVID-19 infection Source: “Pfizer-Biontech Announce Positive Topline Results Of Pivotal Covid-19 Vaccine Study In Adolescents”Links to an external site.. March 21,

Similar Posts

Leave a Reply

Your email address will not be published. Required fields are marked *